Notice to Readers: Expansion of Use of Live Attenuated Influenza Vaccine (FluMist ) to Children Aged 2--4 Years and Other FluMist Changes for the 2007--08 Influenza Season. MMWR 2007. 56 (46): 1217-1219.
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Superseded


This Document Has Been Replaced By: Prevention and control of seasonal influenza with vaccines : recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 influenza season

Notice to Readers: Expansion of Use of Live Attenuated Influenza Vaccine (FluMist ) to Children Aged 2--4 Years and Other FluMist Changes for the 2007--08 Influenza Season. MMWR 2007. 56 (46): 1217-1219.

  • November 23, 2007

Filetype[HTM]


Select to view the document on External site.
This document file type cannot be previewed
English
Details You May Also Like

Details:

  • Description:
    On September 19, 2007, MedImmune Vaccines (Gaithersburg, Maryland) received approval from the Food and Drug Administration (FDA) to expand the use of FluMist , a live, attenuated influenza vaccine (LAIV), to children aged 2--4 years (i.e., 24--49 months). FluMist is an intranasally administered influenza vaccine that was first licensed by the FDA in 2003 for healthy, nonpregnant persons aged 5--49 years (1). Expanding the age indications to include healthy children aged 2--4 years provides another influenza vaccination option for young children. In granting the new approval, FDA emphasized that FluMist is not approved for vaccination of children aged <2 years or adults aged >49 years, and that FluMist safety has not been established in persons with underlying medical conditions predisposing them to influenza-related complications (2). In addition, FluMist should not be administered to persons with asthma or children aged <5 years with recurrent wheezing (1,2).
  • Document Type:
    Journal Article
  • Collection(s):
  • Main Document Checksum:
  • File Type:

Supporting Files

  • No Additional Files
More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov